Source: Eur Respir J 2003; 21: 567-573
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jones H.A., Marino P.S., Shakur B.H., Morrell N.W.. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 2003; 21: 567-573

Member's Comments

No comment yet.

Related content which might interest you: Influence of acute smoking on pulmonary inflammatory cell activity measured by positron emission tomography (PET) in asymptomatic cigarette smokers Source: Annual Congress 2005 - New modalities and application in lung and airway imaging Year: 2005 Imaging the inflammatory activity of sarcoidosis Source: Eur Respir J 2013; 41: 743-751 Year: 2013 The role of positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose in respiratory oncology Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-34-0, page=245 Year: 2004 Measurement of airway inflammation in smokers by means of positron emission tomography Source: Annual Congress 2012 - Functional imaging of the lung parenchyma, tumours and circulation Year: 2012 Downregulation of the peripheral benzodiazepine receptor in macrophages (Mφ) measured by positron emission tomography (PET) in fibrosing alveolitis due to systemic sclerosis Source: Eur Respir J 2003; 22: Suppl. 45, 532s Year: 2003 18F-fluorodeoxyglucose (18FDG) PET pulmonary imaging in COPD Source: International Congress 2015 – CT, PET, MRI modalities: fusion of anatomical and functional variables for lung assessment Year: 2015 The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Source: Eur Respir J 2001; 17: 802-820 Year: 2001 Quantitative 18F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD Source: ERJ Open Res, 7 (3) 00699-2020; 10.1183/23120541.00699-2020 Year: 2021 Rebuttal Source: Annual Congress 2005 - Lung cancer staging: not as simple as it seems? Year: 2005 Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18FDG) can detect radiographically ”occult“ lung cancer (ROLC) in the central airways Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 (18)F-FDG positron emission tomography/computed tomography and pulmonary function in sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 18F-fluorodeoxyglucose (18FDG) PET pulmonary imaging:comparative methodology in COPD patients Source: International Congress 2014 – COPD and PAH related imaging Year: 2014 Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 227s Year: 2001 Uptake of 18fluorodeoxyglucose in the cystic fibrosis lung: a measure of lung inflammation? Source: Eur Respir J 2003; 21: 848-854 Year: 2003 Visualization and quantification of muscarinic receptors by positron emission tomography (PET) in human lung in vivo Source: Eur Respir J 2001; 18: Suppl. 33, 227s Year: 2001 The use of SPECT in preoperative assessment of patients with lung cancer Source: Eur Respir J 2004; 24: 258-262 Year: 2004 Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration Source: Eur Respir J 2009; 33: 201-212 Year: 2009 Imaging in lung cancer: positron emission tomography scan Source: Eur Respir J 2002; 19: 49S-60S Year: 2002 Assessing nodules detected in lung cancer screening: the value of positron emission tomography Source: Eur Respir J 2015; 45: 314-316 Year: 2015 The place of non-invasive techniques (CT - PET - CT) Source: Annual Congress 2007 - Mediastinal staging for NSCLC Year: 2007